SAB Biotherapeutics, Inc.
No enriched coverage for $SABS in the last 7 days.
No SEC Form 4 filings for $SABS in the last 30 days.
SAB Biotherapeutics reported its first-quarter research and development expenses as $13.4 million. This financial detail is important for investors and analysts tracking the company's operational costs and strategic investments in its drug development pipeline. The information, identified by the stock symbol SABS, provides insight into the company's financial activities.
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the ...
